Century Therapeutics, Inc. Restructuring Charges
Century Therapeutics, Inc. (IPSC) reported Restructuring Charges of $0 for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2024-11-05
- Century Therapeutics, Inc. restructuring charges for the quarter ending 2024-09-30 was $0.00.
- Century Therapeutics, Inc. restructuring charges for the quarter ending 2024-06-30 was $0.00.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month |
|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-05 | $0.00 derived: sum of 2 quarters · filed 2024-11-05 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |